{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-041784","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.638486+00:00","generated_at":"2026-05-15T06:40:51.203793+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity","bullets":["Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.","Previously reported ~9% weight loss at 48 mg dose with favorable tolerability; glycemic and liver benefit signals.","Data from Part 3 expected in Q4 2026; primary endpoints are safety and tolerability.","DA-1726 is a dual GLP-1/glucagon (OXM) analog; company aims for differentiated efficacy and simpler titration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-041784","json":"https://secwatch.observer/filing/0001104659-26-041784.json","markdown":"https://secwatch.observer/filing/0001104659-26-041784.md","text":"https://secwatch.observer/filing/0001104659-26-041784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/0001104659-26-041784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926041784/mtva-20260410x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:40:51.203793+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}